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Background: Adjuvant systemic treatment for patients with isolated locoregional recurrence (ILRR) of
breast cancer is based on a single reported randomized trial. The trial, conducted by the Swiss Group for Clinical
Cancer Research, compared tamoxifen (TAM) with observation after complete excision of the ILRR and proper
radiotherapy. We performed a definitive analysis of treatment outcome at >11 years of follow-up, after the
majority of the patients had a subsequent event of interest.
Patient and methods: One hundred and sixty-seven patients with ‘good-risk’ characteristics of disease were
randomized. ‘Good-risk’ was defined as estrogen receptor expression in the ILRR, or having a disease-free
interval of >12 months and a recurrence consisting of three or less tumor nodules, each ≤3 cm in diameter.
Seventy-nine percent of the patients were postmenopausal at randomization.
Results: The median follow-up time of the surviving patients was 11.6 years. The median post ILRR disease-
free survival (DFS) was 6.5 years with TAM and 2.7 years with observation (P = 0.053). The difference was
mainly due to reduction of further local relapses (P = 0.011). In postmenopausal patients, TAM led to an
increase of DFS from 33% to 61% (P = 0.006). In premenopausal women, 5-year DFS was 60%, independent of
TAM medication. For the whole study population, the median post-recurrence overall survival (OS) was 11.2
and 11.5 years in the observation and the TAM group, respectively; premenopausal patients experienced a 5-
year OS of 90% for observation compared with 67% for TAM (P = 0.175), while the respective figures for post-
menopausal patients were both 75%.
Conclusions: These definitive results confirmed that TAM significantly improves the post-recurrence DFS of
patients after local treatment for ILRR. This beneficial effect does not translate into a detectable OS advantage.
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Introduction
Isolated locoregional recurrence (ILRR) after mastectomy has
been associated with a worse prognosis than breast recurrence
after breast-conserving surgery for primary breast cancer. Despite
aggressive local treatment, almost all patients with ILRR after
mastectomy are believed to develop distant metastases eventually
[1]. Progression-free survival at 7 years was 30% in a recent series
of 337 patients who developed ILRR as first relapse manifesta-
tion. Eighty percent of these patients had undergone a mastectomy
and 20% a lumpectomy and breast radiation for their primary
breast cancer [2]. In a more mature series from the Joint Center for
Radiation Therapy, the actuarial rate of freedom from distant
metastases was only 7% at 10 years [3].
The role of systemic adjuvant treatment is well established in
the management of primary breast cancer, but only one randomized
phase III study has been performed to examine tamoxifen (TAM)
for ILRR. In a first analysis of this trial, conducted from 1982 to
1991, we have demonstrated that TAM significantly prolongs
post-ILRR disease-free survival (DFS) at a median observation
time of 6.4 years. There was a more pronounced effect on the
reduction of further local relapses than on the reduction of distant
metastases. Patients eligible for this study had rather favorable
disease characteristics, such as positive estrogen-receptors or, in
the case of unknown receptor status, not more than three nodules,
each ≤3 cm in diameter, and a disease-free interval (DFI) from
primary treatment of at least 1 year [4]. A subsequent analysis
indicated that TAM was associated with increased distant failure
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rates in premenopausal patients, while both distant and local pro-
gression rates were reduced in postmenopausal patients [5]. TAM
had no  significant impact on overall survival (OS). However, the
median survival duration of the study population had not been
reached at a median follow-up of 6.4 years. This is the only ran-
domized study available on systemic therapy of ILRR to reach its
accrual goal. Since even the retrospective series on this subject are
generally small in size, it was important to analyze the mature
long-term follow-up data of this randomized study. We present
here the results of these analyses at a median follow-up of 11.6
years for surviving patients.
Patients and methods
The study design was described previously [4]. One hundred and sixty-seven
‘good risk’ women with ILRR—defined as first reappearance of cancer in the
ipsilateral (side of the primary tumor) chest wall, shoulder, neck and upper
arm, or the axillary, infraclavicular, supraclavicular and cervical lymph nodes
on either side—were included in the study. ‘Good risk’ was defined as estro-
gen receptor (ER) positivity of the recurrence or, in the case of unknown ER
receptor status, a DFI of >12 months, and less than four recurrence nodules
with a maximal diameter of 3 cm. Premenopausal status was defined as occur-
rence of the last menstruation within 1 year from study entry or, in case of a
previous hysterectomy, patient age of <52 years. ER/progesterone receptor
levels of ≥10 fmol/mg cytosol protein using standard methods were considered
positive. Patients pretreated with adjuvant tamoxifen were not eligible for this
study.
The local treatment consisted of radical excision followed by local radio-
therapy of the recurrence site. A total dose of 5000 cGy was given to the
involved region at 200 cGy per fraction, 5 days a week. Patients were stratified
according to menopausal status, adjuvant chemotherapy and axillary node
involvement at diagnosis, and centrally [Swiss Group for Clinical Cancer
Research (SAKK) Coordinating Center, Bern] randomized by telephone to
either observation or systemic treatment (tamoxifen 20 mg per day orally) until
disease progression.
The Kaplan–Meier method was used to estimate distributions of DFS and
OS [6]. Differences in survival distributions were evaluated using the log-rank
test [7] and, additionally, for the DFS using the Gehan–Wilcoxon test. The
difference between the two tests is that the Gehan–Wilcoxon test places more
weight on the beginning of the survival curve and less on the end, whereas the
log-rank test places equal weight upon both. A multivariate analysis using the
Cox proportional hazards model was performed (SAS v. 8.2, SAS Institute
Inc., Carey, NC; S-PLUS v. 6, Insightful Corp., Seattle, WA) [8]. The interaction
between treatment and menopausal status was tested as described previously
[9]. Cumulative incidence functions totalling the overall event probability
were estimated for the competing events and compared between the treatment
arms [10, 11]. All P values were derived from a two-sided test for significance.
Results
Patient characteristics
One hundred and seventy-eight patients entered this study and
were randomized to TAM or observation after resection and radio-
therapy for ILRR of breast cancer. Eleven of 178 patients were
ineligible (6%) due to reasons detailed in the initial publication of
this study [4]. Disease and patient characteristics are summarized
in Table 1. The median follow-up time for this study was 11.6
years for surviving patients.
Table 1. Characteristics of surviving patients
ER, estrogen receptor; PgR, progesterone receptor; TAM, tamoxifen.
Characteristics Observation 
(n = 40)
TAM 
(n = 39)
No. % No. %
Age (years)
Median 52 57
Range 35–75 35–70
Disease-free interval (months)
Median 45 39
Range 2–175 3–149
Primary tumor size (cm)
<2 16 40 12 31
2–5 23 58 25 64
>5 1 3 1 3
Unknown 0 0 1 3
Axillary node involvement
Negative 25 63 21 54
Positive 15 38 15 38
Unknown 0 0 3 8
Adjuvant chemotherapy
Yes 18 45 15 38
No 22 55 23 59
Unknown 0 0 1 3
Locoregional recurrence
Localization
Skin ± chestwall 38 95 34 87
Lymph nodes ± skin 2 5 5 13
Hormonal receptors (ER and PgR)
Determined 25 63 26 67
Not determined 15 38 13 33
Menopausal status
Premenopausal
Nodal status at diagnosis of primary
Negative 9 64 3 43
Positive 5 36 3 43
Unknown 0 0 1 14
Estrogen receptor status
Positive 8 57 4 57
Unknown 6 43 3 43
Previous adjuvant chemotherapy
Yes 6 43 3 43
No 8 57 3 43
Unknown 0 0 1 14
Postmenopausal
Nodal status at diagnosis of primary
Negative 16 62 18 56
Postitive 10 38 12 38
Unknown 0 0 2 6
Estrogen receptor status
Positive 17 65 22 69
Unknown 9 35 10 31
Previous adjuvant chemotherapy
Yes 12 46 12 38
No 14 54 20 63
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Disease-free survival
Disease-free survival was calculated from the day of randomization
until the first event. Possible events were breast cancer recurrence
(local, distant or both), second malignancy or death. The median
time to first event was 2.7 years with observation alone and
6.5 years in the TAM arm (log-rank P = 0.053) (Figure 1). This
difference was even more significant if it was assumed that the
occurrence of relapses was not evenly distributed over time
(Gehan–Wilcoxon P = 0.008). The 5-year DFS rates were 61% in
the TAM arm and 40% in the observation arm. There were four
new events in the TAM arm and two new events in the observation
arm after 9 years. Table 2 lists the results of the multivariate analysis
to examine the influence of a variety of factors on DFS. Treatment
with TAM and a DFI >12 months from first treatment of breast
cancer to local relapse were prognostic for a longer DFS. Meno-
pausal status also became a significant prognostic factor for DFS,
since postmenopausal patients were at greater risk for relapse (P =
0.051). Nodal involvement at study entry was of borderline signif-
icance (P = 0.071).
Table 3 lists the results of the cumulative incidence analysis
of the different types of further relapse at 3, 5 and 10 years. In
accordance with the first analysis of this study, only further local
recurrences were significantly reduced by TAM treatment. The
cumulative incidence of local and distant failure is shown in
Figure 2A and B. Other events, such as death or second cancer,
were too rare to allow statistical analysis.
Overall survival
Overall survival was calculated from the day of randomization
until the date of death or the date the patient was last known to be
alive. Median survival times were 11.5 and 11.2 years in the TAM
and observation arms, respectively (P = 0.79) (Figure 3). The 5-year
survival rate was 73% in the TAM arm and 79% in the observation
arm. Of the 167 patients, 40 are still alive with observation alone
and 39 are undergoing treatment with TAM. Table 4 lists the
results of the multivariate analysis to examine the influence of a
variety of factors on OS. DFI >12 months from first treatment of
breast cancer to local relapse, patient age (cut-off point arbitrarily
set at 65 years) and nodel involvement at study entry had a signifi-
cant impact on OS.
Menopausal status and outcome
The Kaplan–Meier distribution of DFS for both menopausal and
treatment groups is shown in Figure 4. TAM had a significant
impact on relapse reduction only in postmenopausal patients. In
premenopausal women, 5-year DFS was 60% both with and
without TAM. The corresponding figures were 61% and 33%,
respectively, in the postmenopausal patient group (P = 0.006).
The Kaplan–Meier distribution of OS for both menopausal and
treatment groups is plotted in Figure 5. Premenopausal control
patients seem to have a better survival compared with the other
groups, although this difference did not reach statistical signifi-
cance. The 5-year survival for premenopausal control patients was
exceptionally good (90%), while premenopausal TAM patients
had a 5-year OS of only 67% (P = 0.175). These observations
should be interpreted with caution, since the group of premeno-
pausal patients is small (n = 35). The 5-year OS of both postmeno-
pausal patient arms was 75%. There were no events such as death
due to pulmonary embolism or endometrial cancer in both meno-
pausal groups, which could have been attributed to the effect of
TAM.
Discussion
These are the mature results of the randomized SAKK study
addressing the question of systemic treatment for ILRR after mas-
tectomy. In the first analysis at 6.3 years median follow-up, 5-year
DFS was significantly improved with TAM, from 36% to 59%
[4]. In the present long-term analysis at a median follow-up of
11.6 years for surviving patients, we can show that the positive
impact of TAM on DFS is real and persistent. The current analysis
demonstrates a 5-year DFS of 40% in the observation group and
61% in the TAM group.
The positive impact of TAM on DFS did not translate into a
survival benefit. Different factors might have been responsible for
this fact, such as small patient numbers and the low number of
events. The analyses by menopausal status showed that the bene-
ficial effect of TAM on DFS was confined to postmenopausal
patients. This group is also most at risk for death events unrelated
to breast cancer, and the positive impact of TAM on DSF might
thus not have enough time to influence OS in this age group. Pre-
menopausal patients did not benefit from TAM in terms of DFS.
Rather unexpectedly, premenopausal women seemed to be at greater
risk of death if treated with TAM compared with observation.
These differences, however, were not statistically significant and
the patient numbers in the respective subgroups were small. TAM-
induced toxicity would be an explanation for this unexpected
finding; however, there was no evidence for TAM-associated life-
threatening complications or secondary cancers in our patients. Since
most deaths occurred due to disease progression, we speculate that
Figure 1. Disease-free survival by treatment. Ctrl, control; Tam, tamoxifen.
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TAM might have a trophic effect in a subset of premenopausal
breast cancers by elevating circulating estrogens [12].
Premenopausal women with ILRR fulfilling the inclusion cri-
teria of this study had a very good prognosis. In the control arm of
the study, the risk of death was only 10% at 3 and 5 years. This
occurred despite the fact that 40% and 45% of the patients had
already experienced a further relapse at the respective time points.
This excellent survival outcome might reflect good treatment
options for these patients or the fact that premenopausal control
patients mainly experienced further local reappearance of the
Table 2. Multivariate analysis of disease-free survival
aReference values.
Variable Hazard ratio 95% confidence interval P value
Treatment
Surgery + radiotherapy 1.00a
Surgery + radiotherapy + tamoxifen 0.57 0.39–0.84 0.004
Disease-free interval
≤12 months 1.00a
>12 months 0.48 0.26–0.88 0.017
Primary tumor size
<2 cm 1.00a
≥2 cm 1.25 0.81–1.92 0.325
Pretreatment adjuvant chemotherapy
Yes 1.00a
No 1.44 0.81–2.56 0.210
Nodal involvement (primary tumor)
Negative 1.00a
Positive 1.55 0.88–2.71 0.128
Menopausal status (first relapse)
Premenopausal 1.00a
Postmenopausal 1.71 1.00–2.92 0.051
Skin lesion (first relapse)
No 1.00a
Yes 1.04 0.57–1.90 0.889
Nodal involvement (first relapse)
No 1.00a
Yes 1.79 0.95–3.38 0.071
Hormonal receptors 
Unknown 1.00a
Positive 0.96 0.65–1.43 0.851
Age
≤65 years 1.00a
>65 years 1.34 0.83–2.16 0.234
Table 3. Cumulative incidence rates of first failure events
Ctrl, control; TAM, tamoxifen.
First failure incidence (%)
3 year 5 year 10 year
Ctrl TAM Ctrl TAM Ctrl TAM P value
Local relapse alone 21 5 25 8 31 16 0.011
Distant relapse alone 22 15 25 22 25 32 0.387
Distant + local relapse 2 5 4 5 4 7 0.348
Death/second cancer 6 3 7 5 10 7 0.541
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tumor and not distant metastases. Indeed, six patients suffered
from another local relapse, two patients experienced both a local
recurrence and distant metastases, and no patients developed dis-
tant metastases alone during the observation period of the study.
These results are not in accordance with the general observation
that young age is a poor prognostic factor in patients with breast
cancer [13–15]. Rather, they indicate that premenopausal women
presenting with ILRR as first relapse site and fulfilling the good
prognosis criteria defined in our study represent a favorable prog-
nosis selection of breast cancer patients.
In general, ILRR patients with hormone-sensitive disease repre-
sent a favorable subgroup of women relapsing after mastectomy
for breast cancer. Our results indicate that ∼40% of these patients
experience long-term disease freedom after receiving local treat-
ment and TAM. Even without systemic treatment, 30% of patients
are free from further local and distant relapses. This observation
is in accordance with recently published series on ILRR demon-
strating long-term relapse-free survival figures in the range of
30%–40% [16–18]. This is in contrast to the commonly held
notion that almost all patients with ILRR eventually develop distant
metastases [1]. A possible explanation for this apparent discrep-
ancy is the fact that we, as others, in reporting favorable outcomes
[17, 18], were selecting for patients with good prognoses. The
selection criteria of our study, such as ER positivity or a DFI of
>12 months and small volume disease in case of unknown recep-
tor status, were confirmed in other studies as important prognostic
factors for the outcome of ILRR [17–20].
The observation that most patients with ILRR develop distant
metastases [1] has been taken as evidence that ILRR is rather a
marker for metastatic disease than an isolated relapse site and thus
should not be approached with a curative intent. However, in
contrast to this nihilistic approach, recent data indicate that ILRR
itself can serve as a source of distant metastases, which should
Figure 3. Overall-survival by treatment. Ctrl, control; Tam, tamoxifen.
Figure 2. Cumulative incidence analysis of site of first relapse. (A) Local failure; (B) distant failure. Ctrl, control; Tam, tamoxifen.
Figure 4. Disease-free survival of the study population according to 
treatment group and menopausal status. Ctrl pre, premenopausal control; 
Tam pre, premenopausal tamoxifen; Ctrl post, postmenopausal control; Tam 
post, postmenopausal tamoxifen.
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be eradicated as soon and as radically as possible. Fortin et al.
showed, in ILRR patients, that the rate of distant metastases
peaked at 5–6 years compared with a peak incidence at 2 years for
patients without local relapse [21]. This observation is conceiv-
able considering the notion that the later incidence peak represents
metastases originating from ILRR as their source. Thus, the early
and complete eradication of ILRR seems to be an important goal
in achieving maximum cure rates.
Nowadays most patients with ILRR fulfilling the good prog-
nosis criteria of our study have already experienced prolonged
adjuvant treatment with TAM for primary breast cancer. The
results of studies comparing aromatase inhibitors with TAM or
megestrol acetate in hormone-responsive metastatic breast cancer
have clearly shown that aromatase inhibitors are still effective in
TAM-pretreated patients [22–25]. For ILRR patients fulfilling the
poor-risk criteria defined in our study, the question of the value of
combination chemotherapy is still of great relevance. The Inter-
national Breast Cancer Study Group, in collaboration with the Breast
International Group, has initiated a study comparing chemo-
therapy with local treatment alone in patients with locoregional
recurrence of breast cancer (IBCSG Trial 27; http://www.ibcsg.org/
pub_trials_open27-02.shtml).
Appendix
Institutions contributing patients to this study included: Kantons-
spital, St Gallen (B. Thürlimann, H. J. Senn); Ospedale San
Giovanni, Bellinzona (F. Cavalli, M. Varini); Kantonsspital, Basel
Table 4. Multivariate analysis of overall survival
aReference values.
Variable Hazard 
ratio
95% confidence 
interval
P value
Treatment
Surgery + radiotherapy 1.00a
Surgery + radiotherapy + tamoxifen 0.90 0.58–1.39 0.624
Disease free interval
≤12 months 1.00a
>12 months 0.37 0.19–0.72 0.003
Primary tumor size
<2 cm 1.00a
≥2 cm 1.24 0.74–2.08 0.411
Pretreatment adjuvant chemotherapy
Yes 1.00a
No 1.16 0.63–2.13 0.633
Nodal involvement (primary tumor)
Negative 1.00a
Positive 1.53 0.86–2.73 0.150
Menopausal status (first relapse)
Premenopausal 1.00a
Postmenopausal 1.62 0.85–3.07 0.142
Skin lesion (first relapse)
No 1.00a
Yes 1.83 0.89–3.75 0.099
Nodal involvement (first relapse)
No 1.00a
Yes 2.66 1.31–5.41 0.007
Hormonal receptors
Unknown 1.00a
Positive 1.23 0.78–1.95 0.368
Age
≤65 years 1.00a
>65 years 2.11 1.24–3.57 0.006
1221
(F. Harder, J. P. Obrecht); Hôpital Cantonal, Lausanne (S. Ley-
vraz); Hôpital Universitaire, Geneva (P. Alberto); and University
Hospital, Zurich (U. Metzger).
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